vs
Side-by-side financial comparison of Pfizer (PFE) and Southern Company (SO). Click either name above to swap in a different company.
Pfizer is the larger business by last-quarter revenue ($14.5B vs $8.4B, roughly 1.7× Southern Company). Pfizer runs the higher net margin — 18.6% vs 15.9%, a 2.7% gap on every dollar of revenue. On growth, Southern Company posted the faster year-over-year revenue change (8.0% vs 5.0%). Over the past eight quarters, Southern Company's revenue compounded faster (14.0% CAGR vs 4.3%).
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer (1824–1906) and Charles F. Erhart (1821–1891), Pfizer is one of the oldest pharmaceutical companies in North America.
Southern Company is an American gas and electric utility holding company based in the Southern United States. It is headquartered in Atlanta, Georgia, with executive offices located in Birmingham, Alabama. As of 2021 it is the second largest utility company in the U.S. in terms of customer base. Through its subsidiaries it serves 9 million gas and electric utility customers in 6 states. Southern Company's regulated regional electric utilities serve a 120,000-square-mile (310,000 km2) territor...
PFE vs SO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $14.5B | $8.4B |
| Net Profit | $2.7B | $1.3B |
| Gross Margin | — | — |
| Operating Margin | — | 24.0% |
| Net Margin | 18.6% | 15.9% |
| Revenue YoY | 5.0% | 8.0% |
| Net Profit YoY | — | 5.4% |
| EPS (diluted) | $0.47 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.5B | $8.4B | ||
| Q4 25 | $17.6B | $7.0B | ||
| Q3 25 | $16.7B | $7.8B | ||
| Q2 25 | $14.7B | $7.0B | ||
| Q1 25 | $13.7B | $7.8B | ||
| Q4 24 | $17.8B | $6.3B | ||
| Q3 24 | $17.7B | $7.3B | ||
| Q2 24 | $13.3B | $6.5B |
| Q1 26 | $2.7B | $1.3B | ||
| Q4 25 | $-1.6B | $341.0M | ||
| Q3 25 | $3.5B | $1.7B | ||
| Q2 25 | $2.9B | $880.0M | ||
| Q1 25 | $3.0B | $1.3B | ||
| Q4 24 | $410.0M | $466.0M | ||
| Q3 24 | $4.5B | $1.5B | ||
| Q2 24 | $41.0M | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | 70.0% | — | ||
| Q3 25 | 74.9% | — | ||
| Q2 25 | 74.2% | — | ||
| Q1 25 | 79.3% | — | ||
| Q4 24 | 66.7% | — | ||
| Q3 24 | 70.3% | — | ||
| Q2 24 | 75.2% | — |
| Q1 26 | — | 24.0% | ||
| Q4 25 | -9.4% | 13.1% | ||
| Q3 25 | 20.0% | 33.2% | ||
| Q2 25 | 20.8% | 25.3% | ||
| Q1 25 | 20.3% | 25.9% | ||
| Q4 24 | -0.1% | 16.7% | ||
| Q3 24 | 26.6% | 32.6% | ||
| Q2 24 | -0.8% | 30.0% |
| Q1 26 | 18.6% | 15.9% | ||
| Q4 25 | -9.4% | 4.9% | ||
| Q3 25 | 21.3% | 21.9% | ||
| Q2 25 | 19.9% | 12.6% | ||
| Q1 25 | 21.6% | 16.3% | ||
| Q4 24 | 2.3% | 7.3% | ||
| Q3 24 | 25.2% | 21.1% | ||
| Q2 24 | 0.3% | 18.6% |
| Q1 26 | $0.47 | — | ||
| Q4 25 | $-0.29 | $0.38 | ||
| Q3 25 | $0.62 | $1.54 | ||
| Q2 25 | $0.51 | $0.79 | ||
| Q1 25 | $0.52 | $1.21 | ||
| Q4 24 | $0.07 | $0.48 | ||
| Q3 24 | $0.78 | $1.39 | ||
| Q2 24 | $0.01 | $1.09 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PFE
| Product revenues | $11.7B | 81% |
| Alliance revenues | $2.3B | 16% |
| Royalty revenues | $396.0M | 3% |
SO
Segment breakdown not available.
